Daniel Schmolze

814 total citations
30 papers, 369 citations indexed

About

Daniel Schmolze is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Daniel Schmolze has authored 30 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Daniel Schmolze's work include HER2/EGFR in Cancer Research (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Advanced Breast Cancer Therapies (6 papers). Daniel Schmolze is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Advanced Breast Cancer Therapies (6 papers). Daniel Schmolze collaborates with scholars based in United States and Switzerland. Daniel Schmolze's co-authors include Joanne Mortimer, Yuan Yuan, Paul Frankel, Susan E. Yost, Veronica Jones, Colt A. Egelston, Jin Sun Lee, Weihua Guo, Christopher Ruel and James Waisman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Daniel Schmolze

29 papers receiving 365 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Schmolze United States	11	213	130	86	69	55	30	369
Myrto Moutafi United States	12	311 1.5×	121 0.9×	103 1.2×	172 2.5×	98 1.8×	34	519
Liisa Sailas Finland	7	260 1.2×	121 0.9×	179 2.1×	81 1.2×	48 0.9×	11	412
Ji Won Woo South Korea	10	219 1.0×	58 0.4×	118 1.4×	82 1.2×	89 1.6×	18	352
Vesal Yaghoobi United States	10	197 0.9×	67 0.5×	58 0.7×	87 1.3×	79 1.4×	20	330
Shinichiro Tahara Japan	12	116 0.5×	50 0.4×	87 1.0×	208 3.0×	22 0.4×	35	449
Xiu-Zhi Zhu China	7	183 0.9×	96 0.7×	130 1.5×	86 1.2×	38 0.7×	13	310
EC Inwald Germany	6	266 1.2×	98 0.8×	260 3.0×	114 1.7×	81 1.5×	11	517
Tuulia Vallius United States	8	160 0.8×	39 0.3×	84 1.0×	129 1.9×	51 0.9×	16	405
Daniel Bethmann Germany	14	241 1.1×	54 0.4×	101 1.2×	163 2.4×	27 0.5×	28	450
Simon Schallenberg Germany	10	99 0.5×	92 0.7×	75 0.9×	199 2.9×	72 1.3×	36	434

Countries citing papers authored by Daniel Schmolze

Since Specialization

Citations

This map shows the geographic impact of Daniel Schmolze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Schmolze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Schmolze more than expected).

Fields of papers citing papers by Daniel Schmolze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Schmolze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Schmolze. The network helps show where Daniel Schmolze may publish in the future.

Co-authorship network of co-authors of Daniel Schmolze

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Schmolze. A scholar is included among the top collaborators of Daniel Schmolze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Schmolze. Daniel Schmolze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ruel, Nora, et al.. (2025). Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study. Cancer Treatment and Research Communications. 44. 100954–100954. 1 indexed citations

Egelston, Colt A., Susan E. Yost, Paul Frankel, et al.. (2024). A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.. Journal of Clinical Oncology. 42(16_suppl). 1038–1038. 1 indexed citations

Young, Jonathan R., et al.. (2024). Association Between 18F-FDG PET Activity and HER2 Status in Breast Cancer Brain Metastases. Nuclear Medicine and Molecular Imaging. 58(3). 113–119. 1 indexed citations

Schmolze, Daniel, et al.. (2024). Poor response of HER2-positive mucinous carcinomas of breast to neoadjuvant HER2-targeted therapy: A study of four cases. Annals of Diagnostic Pathology. 74. 152396–152396.

Egelston, Colt A., Weihua Guo, Susan E. Yost, et al.. (2023). Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer. Cancer Immunology Immunotherapy. 72(9). 3013–3027. 14 indexed citations

Yuan, Yuan, Susan E. Yost, Yujie Cui, et al.. (2023). Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer. The Oncologist. 28(7). e498–e507. 9 indexed citations

Lavasani, Sayeh, George Somlo, Susan E. Yost, et al.. (2022). Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer. Cancer. 129(5). 740–749. 5 indexed citations

Young, Jonathan R., Julie A. Ressler, Mark S. Shiroishi, et al.. (2022). Association of Relative Cerebral Blood Volume from Dynamic Susceptibility Contrast-Enhanced Perfusion MR with HER2 Status in Breast Cancer Brain Metastases. Academic Radiology. 30(9). 1816–1822. 4 indexed citations

Lee, Jin Sun, Susan E. Yost, Sierra Min Li, et al.. (2022). Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. Cancers. 14(13). 3159–3159. 16 indexed citations

10.

Wakefield, Devin L., et al.. (2022). Molecular Imaging of HER2 in Patient Tissues with Touch Prep-Quantitative Single Molecule Localization Microscopy. Methods in molecular biology. 2394. 231–248. 1 indexed citations

11.

Chang, Sue, Evita Sadimin, Keluo Yao, et al.. (2022). Establishment of a whole slide imaging-based frozen section service at a cancer center. Journal of Pathology Informatics. 13. 100106–100106. 4 indexed citations

12.

Young, Jonathan R., et al.. (2022). Association of lesion contour and lesion composition on MR with HER2 status in breast cancer brain metastases. Magnetic Resonance Imaging. 96. 60–66. 4 indexed citations

13.

Young, Jonathan R., et al.. (2021). Performance of enhancement on brain MRI for identifying HER2 overexpression in breast cancer brain metastases. European Journal of Radiology. 144. 109948–109948. 8 indexed citations

14.

Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2021). Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. European Journal of Cancer. 154. 11–20. 61 indexed citations

15.

He, Ting-Fang, Ruo‐Qian Wang, Daniel Schmolze, et al.. (2020). Occupancy and Fractal Dimension Analyses of the Spatial Distribution of Cytotoxic (CD8+) T Cells Infiltrating the Tumor Microenvironment in Triple Negative Breast Cancer. Biophysical Reviews and Letters. 15(2). 83–98. 2 indexed citations

16.

Jones, Veronica, et al.. (2020). Accuracy of gross intraoperative margin assessment for breast cancer: experience since the SSO-ASTRO margin consensus guidelines. Scientific Reports. 10(1). 17344–17344. 24 indexed citations

17.

He, Ting-Fang, Susan E. Yost, Paul Frankel, et al.. (2020). Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis. PLoS ONE. 15(3). e0229955–e0229955. 20 indexed citations

18.

Wei, Christina, et al.. (2020). Quantitative Impact of the 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) Practice Guideline Update on Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: A Systematic Analysis. Archives of Pathology & Laboratory Medicine. 145(7). 887–890. 4 indexed citations

19.

Jarrett, Angela M., David A. Hormuth, Vikram Adhikarla, et al.. (2020). Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer. Scientific Reports. 10(1). 20518–20518. 27 indexed citations

20.

Schmolze, Daniel, et al.. (2018). MVPNets: Multi-viewing Path Deep Learning Neural Networks for Magnification Invariant Diagnosis in Breast Cancer.. 189–194. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact